Kineta Presents New Preclinical Data On Lead Anti-CD27 Monoclonal Antibody At The Society For Immunotherapy Of Cancer' 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA) presented new preclinical data on its lead anti-CD27 monoclonal antibody at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data showed high binding affinity and specificity, strong T cell activation and proliferation, and NK cell activation. The antibody demonstrated in vivo antitumor efficacy as a single agent and in combination with other immunotherapies in multiple solid and hematological mouse tumor models.
November 03, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta's new preclinical data on its lead anti-CD27 monoclonal antibody shows promising results, potentially boosting investor confidence in the company's oncology-focused immunotherapies.
The positive preclinical data presented by Kineta on its lead anti-CD27 monoclonal antibody could potentially boost investor confidence in the company's ability to develop effective oncology-focused immunotherapies. This could lead to increased demand for the company's stock, potentially driving its price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100